S
Susan C. Fagan
Researcher at University of Georgia
Publications - 183
Citations - 11201
Susan C. Fagan is an academic researcher from University of Georgia. The author has contributed to research in topics: Stroke & Ischemia. The author has an hindex of 53, co-authored 179 publications receiving 10135 citations. Previous affiliations of Susan C. Fagan include University of Texas Health Science Center at Houston & Henry Ford Health System.
Papers
More filters
Journal ArticleDOI
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
Karen L. Furie,Scott E. Kasner,Robert J. Adams,Gregory W. Albers,Ruth L. Bush,Susan C. Fagan,Jonathan L. Halperin,S. Claiborne Johnston,Irene L. Katzan,Walter N. Kernan,Pamela H. Mitchell,Bruce Ovbiagele,Yuko Y. Palesch,Ralph L. Sacco,Lee H. Schwamm,Sylvia Wassertheil-Smoller,Tanya N. Turan,Deidre Wentworth +17 more
TL;DR: Evidence-based recommendations are included for the control of risk factors, interventional approaches for atherosclerotic disease, antithrombotic treatments for cardioembolism, and the use of antiplatelet agents for noncardioembolic stroke.
Journal ArticleDOI
SDF-1 (CXCL12) is upregulated in the ischemic penumbra following stroke: association with bone marrow cell homing to injury.
William D. Hill,David C. Hess,David C. Hess,Angeline Martin-Studdard,Angeline Martin-Studdard,Jo Carothers,Jo Carothers,Jianqing Zheng,Jianqing Zheng,David Hale,Manabu Maeda,Susan C. Fagan,Susan C. Fagan,Susan C. Fagan,James E. Carroll,Simon J. Conway +15 more
TL;DR: Findings suggest SDF-1 is important in the homing of bone marrow-derived cells, especially monocytes, to areas of ischemic injury.
Journal ArticleDOI
Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke
Susan C. Fagan,Susan C. Fagan,Lewis B. Morgenstern,A. Petitta,R. E. Ward,Barbara C. Tilley,John R. Marler,Steven R. Levine,Joseph P. Broderick,Thomas Kwiatkowski,Michael Frankel,Thomas G. Brott,Michael D. Walker +12 more
TL;DR: Treating acute ischemic stroke patients with tPA within 3 hours of symptom onset improves functional outcome at 3 months and is likely to result in a net cost savings to the health care system.
Journal ArticleDOI
Neuroprotective agents for clinical trials in Parkinson’s disease A systematic assessment
Bernard Ravina,Susan C. Fagan,R. G. Hart,Collin A Hovinga,Diane Murphy,Ted M. Dawson,John R. Marler +6 more
TL;DR: Ravina et al. as discussed by the authors used a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) nonhuman primate model that replicates the progressive nature of PD, and observed that minocycline/MPTP-treated animals developed symptoms more rapidly and severely.
Journal ArticleDOI
Targets for Vascular Protection After Acute Ischemic Stroke
TL;DR: The purpose of this review is to identify the pathophysiologic processes involved in vascular damage after ischemia, which may lead to strategies to provide vascular protection in ischemic stroke patients.